NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting
San Francisco, CA September 12-15, 2009
EMERYVILLE, Calif., Aug. 21 /PRNewswire-FirstCall/ -- NovaBay
Pharmaceuticals, Inc. (NYSE-Amex: NBY), a clinical stage company
developing non-antibiotic anti-infective compounds for the
treatment or prevention of a wide range of bacterial, viral, and
fungal infections, will deliver two poster presentations at the
49th Annual Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC) in San Francisco, CA. The two poster
presentations will describe results from new studies of NVC-422, an
Aganocide compound.
Presentation details are as follows:
Poster Title: N,N-dichloro-2,2-dimethyltaurine (NVC-422) has
bactericidal activity against antiseptic and
antibiotic-resistant Staphylococcus aureus
Date/Time: Monday September 14, from 11:15 am to 1:15 pm
(Pacific Time)
Session: 163. Miscellaneous
Abstract Number: E-1468
Location: Hall B
Poster Title: Antimicrobial activity of endogenous and stabilized
derivatives of N-chlorotaurines against representative
microorganisms in the presence of human plasma, serum
and albumin
Date/Time: Monday September 14, from 11:15 am to 1:15 pm
(Pacific Time)
Session: 167-New Topical Antibacterial Agents Including Agents
against C. difficile
Abstract Number: F1-1526
Location: Hall B
"These findings support the compelling therapeutic profile of
NVC-422 as a broad spectrum antimicrobial agent that carries little
potential for resistance through common antiseptic resistance
mechanisms," said Dr. Dmitri Debabov, poster co-author and
assistant director of microbiology and acting head of biology of
NovaBay Pharmaceuticals.
About Aganocide Compounds
The Aganocide compounds are novel, proprietary, synthetic
N-chlorinated antimicrobial molecules specifically designed by
NovaBay to mimic the body's natural defense against infection. The
Aganocide compounds maintain the biological activities while
improving the stability of naturally occurring N-chlorinated
antimicrobial molecules. These highly differentiated compounds may
deliver the same or better efficacy than currently used antibiotics
without contributing to the growing rise of bacterial resistance.
In preclinical trials, the Aganocide compounds have shown to be
highly effective against bacteria, viruses and fungi. They have
also been demonstrated to be effective against bacteria in biofilm,
which render most antibiotics ineffective. These compounds have a
potentially broad therapeutic index providing a high degree of
potency, good tolerability and dosing versatility and
flexibility.
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals is a mid-stage biopharmaceutical company
focused on developing its proprietary and patented Aganocide
compounds, first-in-class, novel, synthetic anti-infective product
candidates that are bioequivalent to the active antimicrobial
molecules generated within white blood cells to treat and prevent a
wide range of infections without causing resistance. NovaBay has
internal development programs aimed at addressing hospital and
respiratory infections. The company has a licensing and research
collaboration agreement with Alcon, Inc. for use of its Aganocides
in the eye, ear and sinus, and in contact lens solutions. NovaBay
has entered into an agreement with Galderma S.A. to develop and
commercialize Aganocides in acne, impetigo and other dermatological
indications. NovaBay and Aganocide are trademarks of NovaBay
Pharmaceuticals, Inc. For more information on NovaBay, visit
www.novabaypharma.com.
Cautionary Information Regarding Forward-Looking
Statements
The statements in this press release of NovaBay's expectations
regarding the Aganocides possessing the characteristics of a broad
spectrum antimicrobial agent that carries little potential for
resistance and the development and commercialization of its
Aganocide compounds through collaborations with corporate partners
and other risks relating to NovaBay and its Aganocide compounds,
including risks that could cause actual results to differ
materially from those projected in the forward-looking statements
in this press release, are detailed in NovaBay's Annual Report on
Form 10-K, under the caption "Risk Factors" in Item 1A of Part I of
that report, which was filed with the Securities and Exchange
Commission on March 31, 2009.
Source: NovaBay Pharmaceuticals, Inc.
CONTACT: Tom Paulson, Chief Financial Officer of NovaBay
Pharmaceuticals, Inc., +1-510-899-8809, tpaulson@novabaypharma.com;
or Media
Relations, Aimee Corso, +1-310-780-2661, acorso@wcpglobal.com for
NovaBay
Pharmaceuticals, Inc.
Web Site: http://www.novabaypharma.com/
